Pars plana vitrectomy for vitreoretinal complications of Behçet uveitis

European Journal of Ophthalmology

Volumn 23, Issue 1, 2013, Pages 119-128

  Mesquida, Marina ^a   Pelegrín, Laura ^a   Llorenç, Victor ^a   Espinosa, Gerard ^a   Ríos, José ^b   Dick, Andrew D ^c   Adán, Alfredo ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Beh et disease; Uveitis; Vitrectomy; Vitreoretinal complications

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; PREDNISOLONE ACETATE; PREDNISONE; STEROID; TOBRAMYCIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; BEHCET DISEASE; CENTRAL RETINAL THICKNESS; CILIARY DISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG MEGADOSE; EYE FUNDUS; EYE SYNECHIA; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAOCULAR PRESSURE; MALE; OPHTHALMOLOGICAL IMPLANT; OPTICAL COHERENCE TOMOGRAPHY; PHACOEMULSIFICATION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA CYSTOID EDEMA; RETINA MACULA HOLE; RETROSPECTIVE STUDY; SURGICAL APPROACH; TREATMENT INDICATION; UVEITIS; VISUAL ACUITY; VITRECTOMY; VITREORETINOPATHY; VITREOUS HEMORRHAGE; VITREOUS OPACITY; DOSE RESPONSE; DRUG IMPLANT; FOLLOW UP; LENSECTOMY; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; SCLERA BUCKLING PROCEDURE; SPAIN; VISUAL ACUITY CHART;

EID: 84877868027     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000194     Document Type: Article

References (31)

1. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 2004; 138: 373-80.
2. Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H. Ocular features of Behçet's disease: an international collaborative study. Br J Ophthalmol 2007; 91: 1579-82.
3. Kaçmaz RO, Kempen JH, Newcomb C, et al; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Group. Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 2008; 146: 828-36.
4. Lee RW, Dick AD. Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behçet's uveitis. Br J Ophthalmol 2010; 94: 269-70.
5. Deuter CM, Zierhut M, Möhle A, Vonthein R, Stöbiger N, Kötter I. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behçet's dis ease. Arthritis Rheum 2010; 62: 2796-805.
6. Deuter CM, Kötter I, Wallace GR, Murray PI, Stübiger N, Zierhut M. Behçet's disease: ocular effects and treatment. Prog Retin Eye Res 2008; 27: 111-36.
7. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-80.
8. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-16.
9. Williams GA, Haller JA, Kuppermann BD, et al; Dexamethasone DDS Phase II Study Group. Dexamethasone posteriorsegment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009; 147: 1048-54.
10. Ozdemir O, Erkam N, Bakkaloglu A. Results of pars plana vitrectomy in Behçet's disease. Ann Ophthalmol 1988; 20: 35-8.
11. Ahn JK, Chung H, Yu HG. Vitrectomy for persistent panuveitis in Behçet's disease. Ocul Immunol Inflamm 2005; 13: 447-53.
12. Soylu M, Demircan N, Pelit A. Pars plana vitrectomy in ocular Behçet's disease. Int Ophthalmol 2001; 24: 219-23.
13. Llorenç V, Keller J, Pelegrín L, Adán A. Pars plana vitrectomy for vitreo-retinal complications of birdshot chorioretinopathy. Ocul Immunol Inflamm 2011; 19: 346-52.
14. Ieki Y, Kiryu J, Kita M, et al. Pars plana vitrectomy for vitreous opacity associated with ocular sarcoidosis resistant to medical treatment. Ocul Immunol Inflamm 2004; 12: 35-43.
15. Bovey EH, Herbort CP. Vitrectomy in the management of uveitis. Ocul Immunol Inflamm 2000; 8: 285-91.
16. Sullu Y, Alotaiby H, Beden U, Erkan D. Pars plana vitrectomy for ocular complications of Behçet's disease. Ophthalmic Surg Lasers Imaging 2005; 36: 292-7.
17. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Kir N, Urgancioglu M. Neovascularization of the optic disc in Behçet's disease. Jpn J Ophthalmol 2006; 50: 256-5.
18. Ozertürk Y, Bardak Y, Durmus M. Vitreoretinal surgery in Behçet's disease with severe ocular complications. Acta Ophthalmol Scand 2001; 79: 192-6.
19. Atmaca LS, Batioglu F, Idil A. Retinal and disc neovascularization in Behçet's disease and efficacy of laser photocoagulation. Graefes Arch Clin Exp Ophthalmol 1996; 234: 94-9.
20. Krause L, Altenburg A, Bechrakis NE, Willerding G, Zouboulis CC, Foerster MH. Intraocular surgery under systemic interferon- alpha therapy in ocular Adamantiades-Behçet's disease. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1617-21.
21. Akova YA, Yilmaz G, Aydin P. Retinal tears associated with panuveitis and Behçet's disease. Ophthalmic Surg Lasers 1999; 30: 762-5.
22. Kerkhoff FT, Lamberts QJ, van den Biesen PR, Rothova A. Rhegmatogenous retinal detachment and uveitis. Ophthalmology 2003; 110: 427-31.
23. Georgalas I, Markomichelakis N, Ladas I. Retinal detachment due to a macular hole in a patient with Behcet disease treated with vitrectomy and silicone oil tamponade. Eur J Ophthalmol 2008; 18: 1023-4.
24. Wu TT, Hong MC. Pars plana vitrectomy with internal limiting membrane removal for a macular hole associated with Behçet's disease. Eye 2009; 23: 1606-7.
25. Benchekroun O, Lahbil D, Lamari H, et al. [Macular damage in Behçet's disease.] J Fr Ophtalmol 2004; 27: 154-9.
26. Oueghlani E, Pavésio CE. Intravitreal triamcinolone injection for unresponsive cystoid macular oedema in probable Behçet's disease as an additional therapy. Klin Monatsbl Augenheilkd 2008; 225: 497-9.
27. Atmaca LS, Yalçindag FN, Ozdemir O. Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behçet's disease. Graefes Arch Clin Exp Ophthalmol 2007; 245: 451-6.
28. Karacorlu M, Mudun B, Ozdemir H, Karacorlu SA, Burumcek E. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet disease. Am J Ophthalmol 2004; 138: 289-91.
29. Chang-Lin JE, Burke JA, Peng Q, et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci 2011; 52: 4605-9.
30. Williams GA, Haller JA, Kuppermann BD, et al; Dexamethasone DDS Phase II Study Group. Dexamethasone posteriorsegment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009; 147: 1048-54.
31. Lowder C, Belfort R Jr, Lightman S, et al; Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545-53.